Earnings Releases·Oct 28, 2026, 7:03 AM ET

Bausch + Lomb — Third Quarter 2026 Earnings Summary

Q3 2026 revenue rose 7% year-over-year to $1.375 billion, while GAAP net income turned profitable at $32 million compared to a $28 million loss in the prior year period; Adjusted EBITDA increased to $325 million from $243 million.
Full-year 2026 guidance was raised across the board: revenue to $5.450–$5.550 billion, constant currency growth to 6.1–8.0%, and Adjusted EBITDA Excluding Acquired IPR&D to $1.090–$1.140 billion.
All three segments posted growth, with Pharmaceuticals up 11% driven by MIEBO® (up 42% to $119 million) and Surgical up 9% led by a 70% increase in premium IOL revenue.
Management confirmed delivery against Investor Day commitments for four consecutive quarters and noted ongoing preparation for the proposed separation from Bausch Health Companies Inc., though risks regarding timing and supply chain disruptions remain.